Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Novartis ricerca costantemente nuovi talenti da inserire nel proprio organico. Visualizza le opportunità di impiego nelle diverse Divisioni e in tutti i paesi.

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

On this page, you can find our annual reporting documents and other disclosures, as well as many of our internal policies, codes, guidelines and commitments.

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp ...

Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction ...

Find information about the Novartis General Meetings.Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.